查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1829133

股骨通路器械市场（按器械类型、鞘套尺寸、应用、最终用户和材料）－全球预测，2025-2032

Femoral Access Devices Market by Device Type, Sheath Size, Application, End User, Material - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年股动脉通路设备市场规模将成长至 46.6 亿美元，复合年增长率为 11.48%。

主要市场统计数据
基准年2024年 19.5亿美元
预计2025年 21.7亿美元
预测年份：2032年 46.6亿美元
复合年增长率（%） 11.48%

简要说明不断发展的股动脉通路设备格局，其中临床需求、设备创新和业务重点正在影响策略选择

随着手术复杂性、器材创新和医疗保健系统需求的不断融合，股动脉通路器材领域正经历着持续的演变。临床医生越来越需要能够提高手术精准度并最大程度减少併发症的工具，而製造商也不断调整产品系列和材料以满足这些期望。同时，不断变化的报销框架、品质指标和医院筹资策略正在塑造门诊手术中心、诊所和医院的采购行为。因此，价值链上的相关人员必须将临床优先事项与营运效率相结合，以改善患者预后并降低围手术期和术后併发症发生率。

如今，临床决策的驱动因素包括手术有效性、设备人体工学以及介入性心臟病学、放射学、神经病学和血管外科的证据。因此，产品差异化不再在于功能性的提升，而是可证明的临床价值、简化的工作流程以及与更广泛的介入设备生态系统的兼容性。为此，设备开发商正在投资材料科学、亲水涂层以及先进的瓣膜和鞘套结构，以满足临床医生的偏好和安全要求。这些进步正在为设备性能带来新的期望，推动竞争格局的重新定位，并促使最终用户仔细审查其对医疗总成本（而不仅仅是单位成本）的影响。

未来的市场参与企业需要在技术创新与监管严谨性和供应链韧性之间取得平衡。临床应用取决于可靠的证据、在临床环境中的易用性以及併发症发生率的显着降低。同时，采购团队将优先考虑能够实现可预测供应、可扩展的供应商关係、缩短手术时间并提高患者吞吐量的产品。本介绍为转型领域提供了一个框架，在该领域，对产品性能、相关人员参与度和营运准备度的策略投资将决定哪些组织能够实现永续的临床应用和付款人认可。

不断发展的临床实践、聚合物和涂层创新以及护理环境的变化如何重新定义设备设计优先顺序和采购行为

股动脉通路器械领域正在经历一系列变革，这得益于临床实践的变革、技术进步以及对手术全期安全性的日益重视。在循环系统、神经科、放射学和血管外科领域，外科医生正在拥抱微创手术，这种手术强调器械外形更小巧、止血控制更佳以及与成像和导航系统的无缝整合。因此，设计重点正转向亲水性涂层、适应性瓣膜系统以及鞘套几何形状，以减少动脉创伤并支援更广泛的手术器械。

同时，材料创新正在重塑产品生命週期。尼龙、聚氨酯和聚四氟乙烯 (PTFE) 材料正在不断改进，以平衡其推入性、抗扭结性和生物相容性。这种材料优化正在带来更可靠的导引器鞘套和扩张器，使其在不同患者解剖结构中保持稳定的性能。因此，供应商正将研发资源投入聚合物化学和涂层技术上，以期实现触觉响应并降低併发症发生率。多腔扩张器和专用导管导引线的出现，反映了当前手术专用器械的持续发展趋势，旨在增强手术控制并降低併发症相关风险。

在营运方面，向门诊和混合护理的转变正在推动设备分销和服务模式的变革。门诊手术中心和门诊专科诊所正在寻求能够简化库存管理并缩短设定时间的套件和设备套装。因此，製造商正在探索附加价值服务，例如供应商管理库存、手术培训计划以及用于设备追踪和临床结果监测的数位化工具。这种转变也推动了设备製造商和医疗保健提供者之间的策略伙伴关係关係，以标准化准入策略，并共同製定促进一致结果的通讯协定。随着这些趋势的融合，竞争格局将有利于那些能够证明临床有效性、操作便利性以及降低整体围手术期风险的机构。

评估2025年不断变化的关税政策和贸易动态将如何再形成筹资策略、价格谈判和供应链弹性决策

2025年，贸易政策和关税实施的变化将为采购股动脉通路器械和零件的组织带来新的复杂性。针对医疗设备进口、零件和原料聚合物的关税调整正在改变某些製造商和经销商的成本结构，尤其是那些供应链面向跨境製造中心的製造商和分销商。这些变化迫使下游相关人员重新评估筹资策略、库存缓衝并实现经销商多元化，以降低成本突然波动带来的风险。

对于进口关键材料（例如特殊聚合物、聚四氟乙烯 (PTFE) 变体和亲水涂层化学品）的製造商而言，关税导致投入成本增加，在某些情况下甚至需要重新评估其生产布局。因此，一些公司正在加速近岸外包和供应商整合，以保护利润率并降低前置作业时间波动。同时，医院和门诊手术中心的采购团队要求提高地租成本和总拥有成本的透明度，并要求供应商提供更清晰的定价驱动因素明细，并展示其在整体医疗保健领域的成本节约价值。

累积影响也影响着策略定价和合约谈判。大型综合医疗系统正利用其采购规模，寻求固定价格、多年期合同，以对冲进一步的关税波动；而规模较小的医疗机构则优先考虑灵活的采购安排，以便快速切换和替换其他产品线。此外，关税环境正在加速围绕产品在地化的讨论，一些目标商标产品製造商正在投资区域製造能力，以减轻关税的影响并提高供应链的弹性。这些变化迫使法律、监管和商业团队更加紧密地合作，以使采购决策与不断变化的贸易条件保持一致，并确保医疗保健的连续性。

高解析度分割分析揭示了设备架构、鞘套尺寸、临床使用、最终用户偏好和材料科学如何推动采用

要了解分段级性能，需要详细了解器械类别、鞘套尺寸、临床使用、最终用户偏好和材料选择。对于扩张器，多腔和单腔的区别决定了交换效率和器械相容性。对于导管导引线，亲水涂层、J 型导丝和直型导丝等亚型决定了导航特性和血管通路策略。从亲水到机械的止血阀选项直接影响出血控制和手术人体工学。导引鞘分为 10+、6+ 和 7-9 French 鞘管，反映了对手术器械相容性和血管创伤的考虑。

鞘套管尺寸细分同样影响临床决策。对于需要较大设备平台的复杂介入手术，通常选择 10Fr 及更大的尺寸，而 6Fr 及较小的尺寸则支援诊断性血管造影术和微创介入。 7Fr-9Fr 尺寸代表了入路创伤和设备相容性之间的折衷。基于应用的细分强调了心臟病学、神经科、放射学和血管外科中设备功能与临床工作流程之间的相互作用。心臟病学涵盖循环系统和介入性心臟病学，其中快速止血和鞘套可操作性是优先事项。神经病学涵盖血管造影术和介入神经放射学，强调非侵入性导航和与神经血管设备的兼容性。放射学涵盖诊断性和介入性放射学，其中需要各种鞘套和导管导引线，血管外科涵盖 EVAR 和周边血管成形术，其中设备的坚固性和密封完整性至关重要。

最终用户细分透过门诊手术中心、诊所和医院来区分采用动态。门诊手术中心分为心臟外科和放射科 ASC，它们需要精简的套件和可预测的供应；诊所分为门诊和专科诊所，它们优先考虑成本效益和易用性；医院分为心臟病医院和多专科医院，它们的采购决策涉及平衡基于数量的合约和临床试验主导的采用。材料细分抓住了聚合物科学在仪器性能中的作用。尼龙变体（包括单丝和多丝纤维）提供不同的拉伸性能和触觉回馈。聚氨酯亚型（例如酯和醚）平衡了柔韧性和耐化学性。 PTFE 选项（包括发泡PTFE 和标准 PTFE）有助于润滑和减少摩擦。这些细分揭示了产品结构、尺寸、临床背景、护理环境和材料特性如何决定规格选择、购买标准和采用曲线。

关于报销、监管和基础设施因素如何影响世界主要地区的采用的策略见解

股动脉通路器材领域的区域动态反映了美洲、欧洲、中东和非洲以及亚太地区不同的医疗保健体系结构、法规环境和投资重点。在美洲，成熟的介入性心臟病学和血管外科计画以及强大的报销框架支持早期采用先进的器械功能和捆绑服务模式。该地区专注于临床疗效和基于价值的采购，鼓励供应商展示降低併发症发生率的成果，并支持在真实环境中检验器械性能的长期临床研究。

在整个欧洲、中东和非洲地区，监管协调工作和公共采购机制正在塑造采购週期和产品註册策略。许多市场的医院和医疗机构将成本控制和标准化设备处方放在首位，这推动了对兼具临床疗效和显着成本效益的设备的需求。此外，介入神经病学和放射学的区域卓越中心正在推动更高临床层面的创新，并影响供应商的定位和伙伴关係模式。

亚太地区市场成熟度参差不齐，诊断与介入服务能力快速扩张。新医院基础设施的投资、门诊手术中心的成长以及心血管和神经血管手术的日益普及，正在推动股动脉通路技术的加速应用。同时，本土製造能力的提升以及对国内生产的政策激励，正鼓励跨国公司调整其供应链布局并寻求合资企业。综上所述，这些区域趋势揭示了供应商如何在满足不同监管和最终用户期望的同时，优先考虑产品发布、临床教育计画和商业策略。

竞争格局审查，详细说明涂层、阀门设计和整合服务产品的创新如何塑造供应商差异化和合作伙伴关係

股动脉通路器械领域的竞争定位正在被重新定义，其重点在于产品创新、策略伙伴关係和供应连续性。优先考虑差异化技术，例如先进的亲水涂层、精密的止血瓣膜设计以及优化的鞘套几何形状以减少动脉创伤，这些技术正在确保介入科医生的认可。许多公司也在扩展其服务组合，包括外科医生培训、手术清单和数据主导的结果支持，这些服务正在推动其应用并强化其临床价值提案。

器械製造商与临床中心之间的策略联盟日益普遍，这使得双方能够共同开发协议化准入方法和上市后调查计画。此类联盟有助于展示实际应用效果，同时为进一步的产品改进铺平道路。同时，一些公司正在采取营运措施来增强製造弹性，例如实现在地化生产，并与关键聚合物和涂层化学品的多元化供应商建立合作关係。这些措施对于缓解供应中断并在不断变化的关税制度下履行合约承诺至关重要。

最后，竞争格局将取决于能否提供能够降低医院库存复杂性并提高手术处理能力的整合解决方案。能够将相容的扩张器、导管导引线、止血阀和鞘套组合成方便临床医生使用的套件，并辅以培训和疗效数据的公司，更有可能获得市场青睐。成功取决于能否证明这些整合产品能够显着提高手术效率、安全性和临床医生满意度。

可行的策略重点，以同步产品创新、製造弹性、临床医生参与和灵活合同，确保持久的市场领导地位

产业领导者应推行协调一致的策略，将产品创新与供应链韧性和临床疗效证据结合。首先，优先投资于能够显着减少血管创伤并改善器械操作的材料和涂层技术，并将这些创新与严格的上市后数据收集相结合，以检验临床效益。证明併发症发生率降低和工作流程简化对于与以疗效为导向的采购委员会和付款相关人员互动至关重要。

其次，多元化製造地，确保关键原材料的替代供应商，以降低关税和地缘政治因素造成的成本波动风险。近岸外包和区域製造伙伴关係可以缩短前置作业时间，并支持与大型医疗系统达成长期商业协议。第三，创建以临床医生为中心的开发模式，提供针对特定手术的套件、实践培训项目和数位化工具，以追踪设备使用情况和临床结果。这些措施可以降低门诊和门诊环境中采用此技术的门槛，同时培养临床医师的长期忠诚度。

第四，强调商业性弹性，尽可能提供分级定价、多年期供应协议和结果挂钩合约。这有助于采购方管理成本不确定性，并协调相关人员之间的奖励。一些地区可能需要与国内製造商合作，或根据当地实践模式客製化临床证据包。透过实施这些优先事项，产业领导者可以强化其市场定位，保护净利率，并扩大不同医疗环境中的临床应用。

透过结合临床医生访谈、监管和临床证据研究以及情境分析的强大混合方法研究途径来获得有意义的策略见解

本研究综合了多条证据，并从一手和二手研究中得出结论。主要输入包括对循环系统、神经科学、放射学和血管外科的介入临床医生、医院和门诊中心的采购和供应链负责人以及设备製造商的研发主管进行结构化访谈。这些访谈旨在收集关于设备性能、采购优先顺序、临床工作流程限制和供应链敏感性的实际观点。

二次研究包括对同行评审的临床文献、监管核准和安全资讯、专利申请以及公开的企业资料进行系统性回顾，以揭示产品平臺和商业策略。在可行的情况下，我们检验了临床登记册和程序结果库，以验证器械的安全性和有效性声明。调查方法强调将临床医生报告的经验与记录在案的临床证据进行交叉检验，以减少偏见并提高见解的可靠性。

分析方法包括跨设备细分领域的比较特征映射、关税和供应链影响的情境分析，以及定性综合，以得出切实可行的建议。我们维持资料来源的透明度，并在证据有限或不断发展的情况下，专注于提升洞察的品质。这种方法的结论对商业性相关人员而言具有可操作性，对寻求循证指导的临床相关人员而言也足够严谨。

核心洞察整合和策略蓝图专注于临床检验、供应链敏捷性和商业性协调，以推动持续采用

股动脉通路器材领域正处于技术进步、临床重点和商业性策略交会的曲折点。材料和器械架构的进步使得通路技术更加安全高效，而护理环境和采购模式的转变正在重塑器械的采购和部署方式。同时，不断变化的贸易政策和供应链压力凸显了製造敏捷性和商业灵活性的必要性。

这些目标是：透过创新和证据产生提供可衡量的临床价值；确保供应链稳健，以确保关键部件的持续供应；并使商业模式与购买者对治疗结果和总成本的期望相一致。能够透过将产品差异化与临床医生参与和灵活的合约模式相结合来实现这些目标的组织，将最有可能在医院、门诊中心和专科诊所获得持续的采用。本文提出的建议为克服该领域的短期挑战和掌握长期机会提供了切实可行的蓝图。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 增加超音波引导下股动脉介入技术的应用以减少血管併发症
  • 加强设备製造商和介入性心臟病专家之间的合作，以客製化股动脉通路解决方案
  • 开发微创、可生物吸收的股动脉通路闭合装置，以促进病患康復
  • 整合人工智慧驱动的影像分析，优化股动脉入路部位选择与手术效率
  • 监管部门的核准加速了新型止血密封剂在股动脉穿刺治疗的应用
  • 一次性预装股动脉通路套件的需求不断增加，以简化导管室工作流程并减少感染

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 股动脉通路器械市场（依器械类型）

  • 扩张器
    • 多重腔
    • 单腔
  • 导管导引线
    • 亲水涂层
    • J型尖头
    • 直尖
  • 止血阀
    • 亲水阀
    • 机械阀
  • 导引鞘
    • 10Fr 或更多
    • 6Fr 或更少
    • 7Fr～9Fr

9. 股动脉通路器械市场（依鞘鞘套尺寸）

  • 10Fr 或更多
  • 6Fr 或更少
  • 7Fr～9Fr

第 10 章股动脉通路器材市场（依应用）

  • 心臟病学
    • 诊断性血管造影术
    • 介入性心臟病学
  • 神经病学
    • 神经影像学
    • 介入神经放射学
  • 放射学
    • 诊断放射学
    • 介入放射学
  • 血管外科
    • EVAR
    • 週边血管成形术

第 11 章股动脉通路器材市场（依最终用户）

  • 门诊手术中心
    • 心臟ASC
    • 放射学
  • 诊所
    • 门诊
    • 专科诊所
  • 医院
    • 心臟病医院
    • 综合医院

第 12 章 股动脉通路装置市场（依材料）

  • 尼龙
    • 单丝尼龙
    • 多丝纤维丝尼龙
  • 聚氨酯
    • 酯类聚氨酯
    • 醚聚氨酯
  • PTFE
    • 膨体聚四氟乙烯
    • 标准聚四氟乙烯

13. 股动脉通路器材市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章。股动脉通路设备市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 股动脉通路器械市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott
    • Teleflex
    • Vasorum Ltd.
    • Haemonetics
    • Cordis
    • Marine Polymer Technologies
    • Access Vascular Inc.
    • Advanced Vascular Dynamics
    • Meril Life Sciences
    • Terumo Corporation
Product Code: MRR-43676CF42AF7

The Femoral Access Devices Market is projected to grow by USD 4.66 billion at a CAGR of 11.48% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.95 billion
Estimated Year [2025] USD 2.17 billion
Forecast Year [2032] USD 4.66 billion
CAGR (%) 11.48%

A concise orientation to the evolving femoral access devices landscape where clinical demand, device innovation, and operational priorities are shaping strategic choices

The femoral access devices landscape is undergoing a period of sustained evolution as procedural complexity, device innovation, and health system imperatives converge. Clinicians increasingly demand tools that enhance procedural precision while minimizing complications, and manufacturers are adapting product portfolios and materials to meet these expectations. In parallel, evolving reimbursement frameworks, quality metrics, and hospital procurement strategies are shaping purchasing behavior across ambulatory surgical centers, clinics, and hospitals. Consequently, stakeholders across the value chain must reconcile clinical priorities with operational efficiency to deliver improved patient outcomes and reduce peri-procedural morbidity.

Today's clinical decision-making is influenced by a combination of procedural efficacy, device ergonomics, and evidence generated from interventional cardiology, radiology, neurology, and vascular surgery. As a result, product differentiation is less about incremental features and more about demonstrable clinical value, streamlined workflows, and compatibility with a broader ecosystem of interventional equipment. In response, device developers are investing in materials science, hydrophilic coatings, and refined valve and sheath architectures that respond to both clinician preferences and safety imperatives. These advances are creating new expectations for device performance, driving competitive repositioning, and prompting end users to scrutinize total cost of care implications rather than unit price alone.

Looking ahead, market participants must balance innovation with regulatory rigor and supply chain resilience. Clinical adoption will depend on robust evidence, ease of use in variable care settings, and demonstrable reductions in complication rates. Meanwhile, procurement teams will prioritize predictable supply, scalable vendor relationships, and products that enable shorter procedure times and faster patient throughput. This introduction frames a sector in transition, one where strategic investments in product performance, stakeholder engagement, and operational readiness will determine which organizations capture sustainable clinical adoption and payer support.

How clinical practice evolution, polymer and coating innovations, and care setting shifts are redefining device design priorities and procurement behaviors

The femoral access devices sector is experiencing a series of transformative shifts driven by clinical practice changes, technological advances, and heightened emphasis on perioperative safety. Operators are increasingly adopting minimally invasive approaches across cardiology, neurology, radiology, and vascular surgery, which places a premium on smaller profiles, improved hemostasis control, and devices that integrate seamlessly with imaging and guidance systems. As a result, design priorities have shifted toward hydrophilic coatings, adaptable valve systems, and sheath geometries that reduce arterial trauma and support a wider range of procedural instruments.

Simultaneously, material innovation is reshaping product lifecycles. Nylon, polyurethane, and PTFE variants are being reformulated to balance pushability, kink resistance, and biocompatibility. These material optimizations are enabling more reliable introducer sheaths and dilators that perform consistently across diverse patient anatomies. In turn, suppliers are reallocating R&D resources toward polymer chemistry and coating technologies that can deliver both tactile responsiveness and reduced complication rates. The emergence of multi-lumen dilators and specialized guidewire tip configurations reflects an ongoing trend toward task-specific instruments that enhance procedural control and reduce exchange-related risks.

Operationally, the shift toward ambulatory and hybrid care settings is prompting changes in device distribution and service models. Ambulatory surgical centers and outpatient specialty clinics demand kits and device bundles that simplify inventory management and reduce setup time. Consequently, manufacturers are exploring value-added services such as vendor-managed inventory, surgical training programs, and digital tools for device tracking and clinical outcomes monitoring. These shifts are also encouraging strategic partnerships between device companies and healthcare providers to co-develop protocols that standardize access strategies and promote consistent outcomes. As these trends coalesce, the competitive landscape will favor organizations that can demonstrate clinical effectiveness, operational convenience, and an ability to reduce overall peri-procedural risk.

Assessment of how evolving tariff policies and trade dynamics in 2025 are reshaping sourcing strategies, pricing negotiations, and supply chain resilience decisions

In 2025, changes in trade policy and tariff implementations have introduced new layers of complexity for organizations sourcing femoral access devices and components. Tariff adjustments targeting medical device imports, components, and raw polymer inputs have altered cost structures for certain manufacturers and distributors, particularly those with supply chains oriented toward cross-border manufacturing hubs. These shifts have compelled downstream stakeholders to reassess sourcing strategies, inventory buffers, and supplier diversification to mitigate exposure to sudden cost transference.

For manufacturers that import critical materials such as specialized polymers, PTFE variants, and hydrophilic coating chemicals, tariffs have translated into higher input costs and, in some cases, a re-evaluation of production footprints. As a result, several firms are accelerating nearshoring initiatives and vendor consolidation to preserve margin and reduce lead-time variability. At the same time, procurement teams within hospitals and ambulatory surgical centers are pushing for greater transparency around landed costs and total cost of ownership, challenging suppliers to provide clearer breakdowns of price drivers and to demonstrate cost-saving value across the care continuum.

The cumulative impact has also influenced strategic pricing and contract negotiations. Large integrated health systems are leveraging purchasing scale to seek fixed-price multi-year agreements that hedge against further tariff volatility, while smaller providers are prioritizing flexible procurement arrangements that allow for rapid substitution or switching to alternative product lines. Moreover, the tariff environment has accelerated conversation around product localization, with some original equipment manufacturers investing in regional manufacturing capabilities to reduce tariff exposure and improve supply chain resilience. These changes are prompting legal, regulatory, and commercial teams to collaborate more closely to align sourcing decisions with evolving trade conditions and to protect continuity of care.

High-resolution segmentation analysis revealing how device architecture, sheath dimensions, clinical application, end-user setting, and material science collectively drive adoption

Understanding segment-level performance requires a granular look at device categories, sheath dimensions, clinical applications, end-user settings, and material selection, each of which drives distinct purchasing logic and clinical value propositions. Based on device type, the market is studied across dilator, guidewire, hemostasis valve, and introducer sheath; within dilators, the distinction between multi-lumen and single lumen configurations informs exchange efficiency and device compatibility, while guidewire subtypes such as hydrophilic coated, J tip, and straight tip determine navigation characteristics and vessel access strategy. Hemostasis valve options ranging from hydrophilic valves to mechanical valves directly affect blood loss management and procedural ergonomics, and introducer sheaths segmented into 10Fr & above, 6Fr & below, and 7Fr-9Fr reflect procedural instrument compatibility and vessel trauma considerations.

Sheath size segmentation similarly frames clinical decision-making; 10Fr & above profiles are often selected for complex interventional procedures requiring larger device platforms, whereas 6Fr & below profiles support diagnostic angiography and less invasive interventions, with 7Fr-9Fr representing a compromise between access trauma and device compatibility. Application-based segmentation highlights the interplay between device features and clinical workflows across cardiology, neurology, radiology, and vascular surgery. Cardiology use encompasses diagnostic angiography and interventional cardiology where rapid hemostasis and sheath maneuverability are prioritized. Neurology covers neuroimaging and neurointervention, emphasizing atraumatic navigation and compatibility with neurovascular devices. Radiology spans diagnostic and interventional radiology with diverse sheath and guidewire requirements, and vascular surgery includes EVAR and peripheral angioplasty procedures where device robustness and seal integrity are critical.

End-user segmentation differentiates adoption dynamics across ambulatory surgical centers, clinics, and hospitals. Ambulatory surgical centers are further profiled into cardiac and radiology ASCs that demand streamlined kits and predictable supply, clinics are split into outpatient and specialty clinics that prioritize cost-effectiveness and ease of use, and hospitals are categorized into cardiac hospitals and multispecialty hospitals where procurement decisions balance volume-based contracts with clinical trial-driven adoption. Material segmentation captures the role of polymer science in device performance. Nylon variants, including monofilament and multifilament forms, offer differing tensile properties and tactile feedback. Polyurethane subtypes such as ester and ether formulations balance flexibility and chemical resistance, while PTFE options, comprising expanded and standard PTFE, contribute to lubricity and reduced friction. Together, these segmentations reveal how product architecture, sizing, clinical context, care setting, and material properties jointly determine specification choices, purchasing criteria, and adoption curves.

Regional dynamics and strategic considerations showing how distinct reimbursement, regulatory, and infrastructure factors are influencing adoption across key global regions

Regional dynamics in the femoral access devices sector reflect divergent healthcare system structures, regulatory environments, and investment priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established interventional cardiology and vascular surgery programs paired with robust reimbursement frameworks support early adoption of advanced device features and bundled service models. This region's focus on clinical outcomes and value-based procurement encourages suppliers to demonstrate reductions in complication rates and to support long-term clinical studies that validate device performance in real-world settings.

Across Europe, the Middle East & Africa, regulatory harmonization efforts and public procurement mechanisms shape purchasing cycles and product registration strategies. Hospitals and health authorities in many markets emphasize cost containment and standardized device formularies, fostering demand for devices that combine clinical efficacy with demonstrable cost benefits. In addition, regional centers of excellence in interventional neurology and radiology drive innovation adoption in higher-acuity sites, influencing vendor positioning and partnership models.

The Asia-Pacific region is characterized by heterogeneous market maturity and rapid capacity expansion in diagnostic and interventional services. Investments in new hospital infrastructure, growth in ambulatory surgical centers, and a rising prevalence of cardiovascular and neurovascular procedures are motivating accelerated uptake of femoral access technologies. Meanwhile, local manufacturing capabilities and policy incentives for domestic production are prompting multinational firms to adapt supply chain footprints and to pursue collaborative ventures. Collectively, these regional trends shape how suppliers prioritize product launches, clinical education programs, and commercial strategies to meet diverse regulatory and end-user expectations.

Competitive landscape insights detailing how innovation in coatings, valve design, and integrated service offerings are shaping vendor differentiation and alliances

Competitive positioning in the femoral access devices arena is being redefined by product innovation, strategic partnerships, and a renewed emphasis on supply continuity. Leading device developers are prioritizing differentiated technologies-such as advanced hydrophilic coatings, refined hemostasis valve designs, and sheath geometries optimized for reduced arterial trauma-to secure preference among interventionalists. Many firms are also expanding their service portfolios to include surgeon training, procedural checklists, and data-driven outcomes support that facilitate adoption and reinforce clinical value propositions.

Strategic collaborations between device manufacturers and clinical centers are increasingly common, enabling co-development of protocolized access approaches and post-market surveillance programs. These alliances help demonstrate real-world performance while creating pathways for incremental product enhancement. At the same time, some companies are pursuing operational initiatives to shore up manufacturing resilience, including localized production and diversified supplier relationships for critical polymers and coating chemistries. Such measures are essential to mitigate supply disruptions and to preserve contract commitments under evolving tariff regimes.

Finally, the competitive landscape is shaped by the capacity to provide integrated solutions that reduce hospital inventory complexity and improve procedural throughput. Organizations that can bundle compatible dilators, guidewires, hemostasis valves, and sheaths into clinician-friendly kits, while supporting them with training and outcomes data, are likely to secure stronger in-market traction. Success will hinge on demonstrating that these integrated offerings deliver measurable improvements in procedural efficiency, safety, and clinician satisfaction.

Actionable strategic priorities to synchronize product innovation, manufacturing resilience, clinician engagement, and flexible contracting to secure durable market leadership

Industry leaders should pursue a coordinated strategy that aligns product innovation with supply chain resilience and clinical outcomes evidence. First, prioritize investments in materials and coating technologies that demonstrably reduce vascular trauma and improve device handling, and couple those innovations with rigorous post-market data collection to validate clinical benefits. Demonstrating reduced complication rates and workflow efficiencies will be pivotal when engaging with outcome-focused procurement committees and payer stakeholders.

Second, diversify manufacturing footprints and secure alternative suppliers for critical raw materials to reduce exposure to tariff-driven cost volatility and geopolitical disruptions. Nearshoring or regional manufacturing partnerships can shorten lead times and support longer-term commercial contracts with large health systems. Third, develop clinician-centric delivery models by offering procedure-specific kits, hands-on training programs, and digital tools that track device utilization and clinical outcomes. These initiatives will lower the barriers to adoption in ambulatory and outpatient settings while building long-term clinician loyalty.

Fourth, emphasize commercial flexibility by offering tiered pricing, multi-year supply agreements, and outcome-linked contracting where feasible. This will enable purchasers to manage cost uncertainty and to align incentives across stakeholders. Finally, invest in targeted regional strategies that respect local regulatory dynamics and care delivery models; in some regions this will require partnerships with domestic manufacturers or tailored clinical evidence packages that speak to regional practice patterns. By executing on these priorities, industry leaders can strengthen market positioning, protect margins, and expand clinical adoption across diverse care settings.

Robust mixed-methods research approach combining clinician interviews, regulatory and clinical evidence review, and scenario analysis to produce validated strategic insights

This research synthesizes multiple streams of evidence to ensure conclusions are grounded in both primary insight and secondary validation. Primary inputs include structured interviews with interventional clinicians across cardiology, neurology, radiology, and vascular surgery, procurement and supply chain leaders at hospitals and ambulatory centers, and R&D executives at device manufacturers. These engagements were designed to elicit practical perspectives on device performance, procurement priorities, clinical workflow constraints, and supply chain sensitivities.

Secondary research encompassed a systematic review of peer-reviewed clinical literature, regulatory approvals and safety communications, patent filings, and publicly available corporate disclosures that illuminate product pipelines and commercial strategies. Where available, clinical registries and procedure outcome repositories were consulted to triangulate claims regarding device safety and efficacy. The methodology emphasized cross-validation between clinician-reported experiences and documented clinical evidence to reduce bias and improve the reliability of insights.

Analytic techniques included comparative feature mapping across device segments, scenario analysis for tariff and supply chain impacts, and qualitative synthesis to derive actionable recommendations. Care was taken to maintain transparency around data sources and to qualify insights where evidence was limited or evolving. This approach ensures that findings are both actionable for commercial stakeholders and sufficiently rigorous for clinical audiences seeking evidence-aligned guidance.

Synthesis of core findings and a strategic roadmap emphasizing clinical validation, supply chain agility, and commercial alignment to drive sustained adoption

The femoral access devices landscape is at an inflection point where technical refinement, clinical priorities, and commercial strategy intersect. Advances in materials and device architecture are enabling safer, more efficient access techniques, while changing care settings and procurement models are reshaping how devices are purchased and deployed. At the same time, trade policy developments and supply chain pressures underscore the need for manufacturing agility and commercial flexibility.

Success in this environment will depend on a disciplined focus on three intertwined objectives: delivering measurable clinical value through innovation and evidence generation, securing supply chain robustness to ensure uninterrupted access to critical components, and aligning commercial models with purchaser expectations around outcomes and total cost of care. Organizations that can operationalize these objectives-by combining product differentiation with clinician engagement and flexible contracting-will be best positioned to capture sustained adoption across hospitals, ambulatory centers, and specialty clinics. The recommendations offered herein provide a practical roadmap to navigate the near-term challenges and to capitalize on long-term opportunities within the sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of ultrasound-guided femoral artery access techniques to reduce vascular complications
  • 5.2. Increasing collaboration between device manufacturers and interventional cardiologists for customized femoral access solutions
  • 5.3. Development of minimally invasive bioresorbable femoral access closure devices to enhance patient recovery
  • 5.4. Integration of AI-driven imaging analytics to optimize femoral access site selection and procedural efficiency
  • 5.5. Regulatory approvals accelerating introduction of novel hemostatic sealants for femoral arterial puncture management
  • 5.6. Emerging demand for single-use preloaded femoral access kits to streamline catheterization lab workflows and reduce infection

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Femoral Access Devices Market, by Device Type

  • 8.1. Dilator
    • 8.1.1. Multi-Lumen
    • 8.1.2. Single Lumen
  • 8.2. Guidewire
    • 8.2.1. Hydrophilic Coated
    • 8.2.2. J Tip
    • 8.2.3. Straight Tip
  • 8.3. Hemostasis Valve
    • 8.3.1. Hydrophilic Valve
    • 8.3.2. Mechanical Valve
  • 8.4. Introducer Sheath
    • 8.4.1. 10Fr & Above
    • 8.4.2. 6Fr & Below
    • 8.4.3. 7Fr-9Fr

9. Femoral Access Devices Market, by Sheath Size

  • 9.1. 10Fr & Above
  • 9.2. 6Fr & Below
  • 9.3. 7Fr-9Fr

10. Femoral Access Devices Market, by Application

  • 10.1. Cardiology
    • 10.1.1. Diagnostic Angiography
    • 10.1.2. Interventional Cardiology
  • 10.2. Neurology
    • 10.2.1. Neuroimaging
    • 10.2.2. Neurointervention
  • 10.3. Radiology
    • 10.3.1. Diagnostic Radiology
    • 10.3.2. Interventional Radiology
  • 10.4. Vascular Surgery
    • 10.4.1. EVAR
    • 10.4.2. Peripheral Angioplasty

11. Femoral Access Devices Market, by End User

  • 11.1. Ambulatory Surgical Center
    • 11.1.1. Cardiac ASC
    • 11.1.2. Radiology ASC
  • 11.2. Clinic
    • 11.2.1. Outpatient Clinic
    • 11.2.2. Specialty Clinic
  • 11.3. Hospital
    • 11.3.1. Cardiac Hospital
    • 11.3.2. Multispecialty Hospital

12. Femoral Access Devices Market, by Material

  • 12.1. Nylon
    • 12.1.1. Monofilament Nylon
    • 12.1.2. Multifilament Nylon
  • 12.2. Polyurethane
    • 12.2.1. Ester Polyurethane
    • 12.2.2. Ether Polyurethane
  • 12.3. PTFE
    • 12.3.1. Expanded PTFE
    • 12.3.2. Standard PTFE

13. Femoral Access Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Femoral Access Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Femoral Access Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott
    • 16.3.2. Teleflex
    • 16.3.3. Vasorum Ltd.
    • 16.3.4. Haemonetics
    • 16.3.5. Cordis
    • 16.3.6. Marine Polymer Technologies
    • 16.3.7. Access Vascular Inc.
    • 16.3.8. Advanced Vascular Dynamics
    • 16.3.9. Meril Life Sciences
    • 16.3.10. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY SHEATH SIZE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY SHEATH SIZE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MATERIAL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MATERIAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS FEMORAL ACCESS DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA FEMORAL ACCESS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA FEMORAL ACCESS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA FEMORAL ACCESS DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE FEMORAL ACCESS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST FEMORAL ACCESS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA FEMORAL ACCESS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC FEMORAL ACCESS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN FEMORAL ACCESS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC FEMORAL ACCESS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION FEMORAL ACCESS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS FEMORAL ACCESS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 FEMORAL ACCESS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO FEMORAL ACCESS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. FEMORAL ACCESS DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. FEMORAL ACCESS DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. FEMORAL ACCESS DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DILATOR, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DILATOR, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DILATOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DILATOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DILATOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DILATOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DILATOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DILATOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTI-LUMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTI-LUMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTI-LUMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTI-LUMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTI-LUMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTI-LUMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY SINGLE LUMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY SINGLE LUMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY SINGLE LUMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY SINGLE LUMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY SINGLE LUMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY SINGLE LUMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY GUIDEWIRE, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY GUIDEWIRE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY GUIDEWIRE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY GUIDEWIRE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY GUIDEWIRE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY GUIDEWIRE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY GUIDEWIRE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY J TIP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY J TIP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY J TIP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY J TIP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY J TIP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY J TIP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY STRAIGHT TIP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY STRAIGHT TIP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY STRAIGHT TIP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY STRAIGHT TIP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY STRAIGHT TIP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY STRAIGHT TIP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HEMOSTASIS VALVE, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HEMOSTASIS VALVE, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HEMOSTASIS VALVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HEMOSTASIS VALVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HEMOSTASIS VALVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HEMOSTASIS VALVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HEMOSTASIS VALVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HEMOSTASIS VALVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HYDROPHILIC VALVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HYDROPHILIC VALVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HYDROPHILIC VALVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HYDROPHILIC VALVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HYDROPHILIC VALVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HYDROPHILIC VALVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MECHANICAL VALVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MECHANICAL VALVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MECHANICAL VALVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MECHANICAL VALVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MECHANICAL VALVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MECHANICAL VALVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTRODUCER SHEATH, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTRODUCER SHEATH, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTRODUCER SHEATH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTRODUCER SHEATH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTRODUCER SHEATH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTRODUCER SHEATH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTRODUCER SHEATH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTRODUCER SHEATH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 10FR & ABOVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 10FR & ABOVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 10FR & ABOVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 10FR & ABOVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 10FR & ABOVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 10FR & ABOVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 6FR & BELOW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 6FR & BELOW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 6FR & BELOW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 6FR & BELOW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 6FR & BELOW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 6FR & BELOW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 7FR-9FR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 7FR-9FR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 7FR-9FR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 7FR-9FR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 7FR-9FR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 7FR-9FR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY SHEATH SIZE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY SHEATH SIZE, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 10FR & ABOVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 10FR & ABOVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 10FR & ABOVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 10FR & ABOVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 10FR & ABOVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 10FR & ABOVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 6FR & BELOW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 6FR & BELOW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 6FR & BELOW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 6FR & BELOW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 6FR & BELOW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 6FR & BELOW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 7FR-9FR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 7FR-9FR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 7FR-9FR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 7FR-9FR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 7FR-9FR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY 7FR-9FR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DIAGNOSTIC ANGIOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DIAGNOSTIC ANGIOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DIAGNOSTIC ANGIOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DIAGNOSTIC ANGIOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DIAGNOSTIC ANGIOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DIAGNOSTIC ANGIOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROIMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROIMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROIMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROIMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROIMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROIMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROINTERVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROINTERVENTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROINTERVENTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROINTERVENTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROINTERVENTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NEUROINTERVENTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY RADIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY RADIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY RADIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY RADIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY RADIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY RADIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY RADIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY RADIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DIAGNOSTIC RADIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DIAGNOSTIC RADIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DIAGNOSTIC RADIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DIAGNOSTIC RADIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DIAGNOSTIC RADIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY DIAGNOSTIC RADIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY VASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY VASCULAR SURGERY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY VASCULAR SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY VASCULAR SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY VASCULAR SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY VASCULAR SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY VASCULAR SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY VASCULAR SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY EVAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY EVAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY EVAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY EVAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY EVAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY EVAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY PERIPHERAL ANGIOPLASTY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY PERIPHERAL ANGIOPLASTY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY PERIPHERAL ANGIOPLASTY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY PERIPHERAL ANGIOPLASTY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY PERIPHERAL ANGIOPLASTY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY PERIPHERAL ANGIOPLASTY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIAC ASC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIAC ASC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIAC ASC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIAC ASC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIAC ASC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIAC ASC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY RADIOLOGY ASC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY RADIOLOGY ASC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY RADIOLOGY ASC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY RADIOLOGY ASC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY RADIOLOGY ASC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY RADIOLOGY ASC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CLINIC, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CLINIC, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY OUTPATIENT CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY OUTPATIENT CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY OUTPATIENT CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY OUTPATIENT CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIAC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIAC HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIAC HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIAC HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIAC HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY CARDIAC HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTISPECIALTY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTISPECIALTY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTISPECIALTY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTISPECIALTY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTISPECIALTY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTISPECIALTY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NYLON, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NYLON, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NYLON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NYLON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NYLON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NYLON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NYLON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY NYLON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MONOFILAMENT NYLON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MONOFILAMENT NYLON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MONOFILAMENT NYLON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MONOFILAMENT NYLON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MONOFILAMENT NYLON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MONOFILAMENT NYLON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTIFILAMENT NYLON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTIFILAMENT NYLON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTIFILAMENT NYLON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTIFILAMENT NYLON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTIFILAMENT NYLON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY MULTIFILAMENT NYLON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY POLYURETHANE, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY POLYURETHANE, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY POLYURETHANE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY POLYURETHANE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY POLYURETHANE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY POLYURETHANE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY POLYURETHANE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY POLYURETHANE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY ESTER POLYURETHANE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY ESTER POLYURETHANE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY ESTER POLYURETHANE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY ESTER POLYURETHANE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY ESTER POLYURETHANE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY ESTER POLYURETHANE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY ETHER POLYURETHANE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY ETHER POLYURETHANE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY ETHER POLYURETHANE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY ETHER POLYURETHANE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY ETHER POLYURETHANE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY ETHER POLYURETHANE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY PTFE, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY PTFE, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY PTFE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY PTFE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY PTFE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY PTFE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL FEMORAL ACCESS DEVICES MARKET SIZE, BY PTFE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL FEMORAL ACCESS D